摘要
目的评估人附睾分泌蛋白4(HE4)判断卵巢癌复发的灵敏度和特异度。方法 30例上皮性卵巢癌患者作为研究组,经过满意的肿瘤细胞减灭术和术后正规化疗后血清HE4和糖类抗原125(CA125)均降至正常。同时选取30例良性附件手术患者作为对照组。定期进行血清HE4和CA125检测,观察HE4判断卵巢癌复发的灵敏度和特异度。结果 CA125诊断卵巢癌复发的灵敏度和特异度分别为73.33%和86.67%。HE4诊断卵巢癌复发的灵敏度和特异度分别为86.67%和93.33%。HE4+CA125联合诊断卵巢癌复发的灵敏度和特异度分别为93.33%和93.33%。结论 HE4判断卵巢癌术后复发优于CA125,两者联合检测灵敏度、特异度更高。
引文
[1]Rosen DG,Wang L,Atkinson JN,et al.Potential markersthat complement expression of CA125 in epithelial ovariancancer.Gynecol Oncol,2005,99(2):267-277.
[2]Plotti F,Capriglione S,Terranova C,et al.Does HE4 havea role as biomarker in the recurrence of ovarian cancer?Tumour Biol,2012,33(6):2117-2123.
[3]Schummer M,Drescher C,Forrest R,et al.Evaluation ofovarian cancer remission markers HE4,MMP7 and Mesothelinby comparison to the established marker CA125.Gynecol Oncol,2012,125(1):65-69.